Mirai Tumaini E, Kilonzo Kajiru G, Sadiq Abid M, Muhina Ibrahim Ali Ibrahim, Kyala Norman J, Marandu Annette A, Gharib Sarah K, Costantine Andrea R, Mkwizu Elifuraha W, Howlett William P, Shao Elichilia R, Nyakunga Gissela B, Akrabi Huda F, Kshettry Vibhu R, Maro Venance P, Chamba Nyasatu G, Lyamuya Furaha S
Department of Internal Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Department of Internal Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241306492. doi: 10.1177/23259582241306492.
Chronic systemic inflammation from human immunodeficiency virus (HIV) may cause metabolic abnormalities in lipid metabolism. Additionally, the development of metabolic syndrome has been associated with specific anti-retroviral therapy, particularly dolutegravir. This study aimed to determine the prevalence and associated factors of metabolic syndrome among people living with HIV on dolutegravir-based anti-retroviral therapy.
This was an analytical cross-sectional study conducted between October 1, 2022, and March 31, 2023, among 312 people living with HIV. A structured questionnaire was used to collect socio-demographic and clinical characteristics including anthropometric indices and a blood pressure reading. A blood sample was collected to measure plasma glucose levels and serum lipid levels. The outcome being metabolic syndrome, odds ratios were evaluated using logistic regression analysis, and a -value of <.05 was considered statistically significant.
The prevalence of metabolic syndrome was 42.3%. Waist circumference (73%) and reduced high-density lipoprotein cholesterol (59.9%) were the most prevalent components. Factors associated with metabolic syndrome were patients aged 18-44 years (aOR: 3.10; 95% CI: 1.24-7.79; = .016), female gender (aOR: 5.40; 95% CI: 2.07-14.13; = .001), no physical activity (aOR: 4.00; 95% CI: 1.05-15.10; = .042), and patients who earned >300 000 Tanzanian shillings per month (aOR: 2.15; 95% CI: 1.07-4.32; = .032).
The prevalence of metabolic syndrome among patients on dolutegravir-based therapy is high. There is a need to adhere to routine screening of metabolic syndrome among people living with HIV on dolutegravir-based anti-retroviral therapy.
人类免疫缺陷病毒（HIV）引起的慢性全身炎症可能导致脂质代谢出现代谢异常。此外，代谢综合征的发生与特定的抗逆转录病毒疗法有关，尤其是多替拉韦。本研究旨在确定接受基于多替拉韦的抗逆转录病毒治疗的HIV感染者中代谢综合征的患病率及相关因素。
这是一项于2022年10月1日至2023年3月31日期间对312名HIV感染者开展的分析性横断面研究。使用结构化问卷收集社会人口统计学和临床特征，包括人体测量指标和血压读数。采集血样以测量血浆葡萄糖水平和血脂水平。以代谢综合征为研究结果，采用逻辑回归分析评估比值比，P值<0.05被认为具有统计学意义。
代谢综合征的患病率为42.3%。腰围（73%）和高密度脂蛋白胆固醇降低（59.9%）是最常见的组成部分。与代谢综合征相关的因素包括年龄在18 - 44岁的患者（调整后比值比：3.10；95%置信区间：1.24 - 7.79；P = 0.016）、女性（调整后比值比：5.40；95%置信区间：2.07 - 14.13；P = 0.001）、无体育活动（调整后比值比：4.00；95%置信区间：1.05 - 15.10；P = 0.042）以及每月收入超过30万坦桑尼亚先令的患者（调整后比值比：2.15；95%置信区间：1.07 - 4.32；P = 0.032）。
接受基于多替拉韦治疗的患者中代谢综合征的患病率很高。有必要对接受基于多替拉韦的抗逆转录病毒治疗的HIV感染者进行代谢综合征的常规筛查。
